1. Date of occurrence of the event: 2021/11/11
2. Company name: OBI Pharma Inc.
3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
4. Reciprocal shareholding ratios: Not applicable
5. Cause of occurrence: The Company has received the approval letter from MOEAIC regarding the intellectual property rights licensing of OBI’s cancer therapies in China. The licensing deal was resolved by the Company’s Board of Directors on September 28, 2020. Please refer to the Company’s material information announcement on the same date. Further announcement will be made once the Company finished signing the contract.
6. Countermeasures: None
7. Any other matters that need to be specified: None